BioRestorative Therapies Awarded an STTR Phase I Grant to Explore the Therapeutic Effects of PEG-Peptide Hydrogel-Encapsulated Hypoxic Bone Marrow Stem Cells

BioRestorative Therapies, Inc. announced that it has been awarded a Small Business Technology Transfer (STTR) Phase I grant for $256,000 to evaluate the therapeutic effects on the company’s hypoxic cultured bone marrow derived MSCs after encapsulation with a PEG-peptide hydrogel.